MAR002 for Acromegaly

This trial explores a new treatment called MAR002 for individuals with acromegaly, a condition characterized by excessive growth hormone production. The main goal is to assess the safety and tolerability of different doses of MAR002 when administered as an injection under the skin. Participants with acromegaly who have had a pituitary tumor confirmed by a doctor and have experienced high levels of growth hormone in the past are suitable candidates for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants an opportunity to contribute to significant advancements in acromegaly treatment.

Research has shown that MAR002 is likely safe based on earlier studies. Participants in these studies did not experience serious side effects, even at higher doses, indicating that the treatment was well-tolerated. No safety concerns were directly linked to the drug, suggesting that MAR002 is generally safe for use.¹²³⁴⁵

Most treatments for acromegaly, like somatostatin analogs, work by reducing growth hormone production. But MAR002 is different because it targets the growth hormone receptor directly, potentially providing a more precise approach. Administered as a subcutaneous injection, this treatment could offer a new option for patients who struggle with current therapies. Researchers are particularly excited about MAR002's potential to better manage the condition with fewer side effects, making life easier for those with acromegaly.

Studies have shown that MAR002 can effectively lower IGF-1 levels, which are often elevated in people with acromegaly. In previous research, MAR002 reduced IGF-1 levels by up to 52% at the highest dose. This effect lasted for up to 43 days, demonstrating its prolonged efficacy. As a long-acting antibody, the treatment remains in the body longer, providing sustained action. Overall, these findings suggest that MAR002 could be a strong option for managing acromegaly symptoms.³⁴⁶⁷⁸